CIK 0001347178 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 216.1 M | 254.4 M | ||
| Net income (USD) | 23.3 M | 115.6 M | ||
| Diluted EPS (USD/shares) | -3.74 | 0.11 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-09 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-19 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-13 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-05 | 8-K | 8-K items 2.02,9.01 | 2026-08-05 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 4 | 4 | 2026-06-04 |
| 2026-06-08 | 3 | 3 | 2026-06-04 |
| 2026-06-05 | S-8 | S-8 | |
| 2026-06-05 | 8-K | 8-K items 5.07 | 2026-06-04 |
| 2026-05-20 | 4 | 4 | 2026-05-18 |
| 2026-05-12 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-06 | 8-K | 8-K items 2.02,9.01 | 2026-05-06 |
| 2026-05-05 | EFFECT | EFFECT items ,, | |
| 2026-04-29 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-04-24 | CORRESP | CORRESP | |
| 2026-04-24 | 4 | 4 | 2026-04-22 |
| 2026-04-24 | 3 | 3 | 2026-04-22 |
| 2026-04-23 | ARS | ARS | 2025-12-31 |
Forms on file (last 1,000): 4 358, 8-K 254, SC 13G/A 112, 10-Q 52, SC 13G 36, 3 25, DEFA14A 20, 144 19. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=VNDA (0.002 USD), /gw/filings/filings?ticker=VNDA&form=8-K, /gw/filings/facts?ticker=VNDA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange